Project Grant R34AI186857
Award Date
6/2/25
Completion Date
5/31/26
Dollars Obligated
$241K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
This federal Project Grant award, valued at $155,227.00 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to generate proof-of-concept data on a novel treatment strategy for Mycobacterium abscessus (MAB) chronic lung disease. The primary objective is to investigate whether a monoclonal antibody (CMTX-101) can effectively disrupt MAB biofilms in the lungs, which is a key factor limiting...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $895,538 to support research aimed at developing shorter and more effective oral treatment regimens for Mycobacterium abscessus pulmonary disease. The research seeks to identify optimized drug combinations, including both FDA-approved agents and novel preclinical/clinical candidates, that can rapidly reduce...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to develop novel therapeutic strategies for treating mucormycosis, a deadly invasive fungal infection. The $750,815 award, effective March 25, 2025 through February 28, 2030, will be carried out by the University of Maryland, Baltimore. The key objectives of this research project are to: 1) Examine the...
The federal Project Grant award R01AI175935 for $3,492,664.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define immunologic and transcriptomic signatures of Mycobacterium avium complex (MAC) pulmonary disease and microbiologic treatment response. The award funds the collection of longitudinal blood and sputum samples from patients starting treatment for MAC pulmonary...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $201,549 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Medical University of South Carolina (MUSC) to study metabolic syndrome outcomes among tuberculosis (TB) patients in Tanzania. The key products and services to be delivered under this grant include: Measuring and characterizing a set of blood-based and anthropometric metabolic markers, as well as TB severity, among TB...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,413,412 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Texas Biomedical Research Institute to study mechanisms for controlling Mycobacterium tuberculosis (MTB) infection in the lungs. The project aims to understand the immune responses generated by an attenuated, live-replicating MTB strain that has demonstrated protective efficacy in non-human primate models....
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $147,656 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to St. Jude Children's Research Hospital Inc. The grant supports research to determine: 1) the specificity underlying mucin-mediated autolysis inhibition in Streptococcus pneumoniae; 2) the impact of mucin-mediated autolysis inhibition on pneumococcal cytotoxicity; and 3) the genetic determinants required for prolonged...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $749,414 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University for research on the role of macrophage drug efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis. The primary objectives are to: 1) define the role of MDR1 in M.TB survival in macrophages; 2) determine if HSF1 activation or MDR1 inhibition can shorten M.TB sterilization by TB drugs;...
This federal Project Grant award of $558,747.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research on a novel link between calcineurin, amino acid permease, and protein kinase A in virulence in the fungus Mucor, which causes the life-threatening infection mucormycosis. The research aims to identify key transcription factors regulated by calcineurin, elucidate the roles of the amino acid...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $587,318 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Oregon Health & Science University (OHSU) to optimize the structural features of the antimalarial drug candidate ELQ-596 for once-monthly oral prophylaxis in humans. The project aims to develop a next generation of ELQ compounds with improved intrinsic anti-plasmodial activity, enhanced efficacy in animal models, and...